Pulmonary toxoplasmosis.
D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance; D011014:Pneumonia / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology; D011739:Pyrimethamine / Q000627:therapeutic use; D013411:Sulfadiazine / Q000627:therapeutic use; D013416:Sulfamerazine / Q000627:therapeutic use; D013418:Sulfamethazine / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology; D000096926:Benzenesulfonamides
D004338:Drug Combinations; D011739:Pyrimethamine; D013411:Sulfadiazine; D013416:Sulfamerazine; D013418:Sulfamethazine; C014873:trisulfapyrimidine; D000096926:Benzenesulfonamides